NASDAQ:RSLS - Reshape Lifesciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.29 -0.09 (-3.78 %)
(As of 06/24/2018 12:59 PM ET)
Previous Close$2.29
Today's Range$2.25 - $2.40
52-Week Range$2.08 - $79.20
Volume195,220 shs
Average Volume254,442 shs
Market Capitalization$5.94 million
P/E Ratio-0.05
Dividend YieldN/A
Reshape Lifesciences logoReShape Lifesciences Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company develops the vBloc System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It has collaboration with Mayo Clinic. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

Receive RSLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment


Debt-to-Equity RatioN/A
Current Ratio0.61
Quick Ratio0.29


Trailing P/E Ratio-0.05
Forward P/E Ratio-0.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.29 million
Price / Sales4.44
Cash FlowN/A
Price / CashN/A
Book Value$38.22 per share
Price / Book0.06


EPS (Most Recent Fiscal Year)($47.68)
Net Income$-33,810,000.00
Net Margins-1,715.25%
Return on Equity-69.19%
Return on Assets-60.38%


Outstanding Shares2,500,000

The Truth About Cryptocurrencies

Reshape Lifesciences (NASDAQ:RSLS) Frequently Asked Questions

What is Reshape Lifesciences' stock symbol?

Reshape Lifesciences trades on the NASDAQ under the ticker symbol "RSLS."

When did Reshape Lifesciences' stock split? How did Reshape Lifesciences' stock split work?

Reshape Lifesciences shares reverse split before market open on Monday, June 4th 2018. The 1-15 reverse split was announced on Friday, June 1st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 1st 2018. An investor that had 100 shares of Reshape Lifesciences stock prior to the reverse split would have 7 shares after the split.

How were Reshape Lifesciences' earnings last quarter?

Reshape Lifesciences Inc (NASDAQ:RSLS) announced its quarterly earnings results on Monday, May, 14th. The medical device company reported ($5.40) EPS for the quarter. The medical device company earned $0.95 million during the quarter. Reshape Lifesciences had a negative return on equity of 69.19% and a negative net margin of 1,715.25%. View Reshape Lifesciences' Earnings History.

When is Reshape Lifesciences' next earnings date?

Reshape Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Reshape Lifesciences.

Who are some of Reshape Lifesciences' key competitors?

Who are Reshape Lifesciences' key executives?

Reshape Lifesciences' management team includes the folowing people:
  • Mr. Dan W. Gladney, Chairman, Chief Exec. Officer and Pres (Age 65)
  • Dr. Mark B. Knudson Ph.D., Co-Founder and Special Advisor to the CEO (Age 69)
  • Mr. Scott P. Youngstrom, Sr. VP of Fin. & CFO (Age 58)
  • Mr. Naqeeb A. Ansari, VP of International Sales & US Veterans Admin. Hospitals (Age 57)
  • Mr. Jon T. Tremmel, Consultant to the CEO & Director (Age 72)

Has Reshape Lifesciences been receiving favorable news coverage?

Media stories about RSLS stock have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Reshape Lifesciences earned a news sentiment score of 0.10 on Accern's scale. They also assigned news articles about the medical device company an impact score of 47.79 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Reshape Lifesciences?

Shares of RSLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Reshape Lifesciences' stock price today?

One share of RSLS stock can currently be purchased for approximately $2.29.

How big of a company is Reshape Lifesciences?

Reshape Lifesciences has a market capitalization of $5.94 million and generates $1.29 million in revenue each year. The medical device company earns $-33,810,000.00 in net income (profit) each year or ($47.68) on an earnings per share basis. Reshape Lifesciences employs 83 workers across the globe.

How can I contact Reshape Lifesciences?

Reshape Lifesciences' mailing address is 1001 Calle Amanecer, San Clemente CA, 92673. The medical device company can be reached via phone at 949-429-6680 or via email at [email protected]

MarketBeat Community Rating for Reshape Lifesciences (RSLS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about Reshape Lifesciences and other stocks. Vote "Outperform" if you believe RSLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RSLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.